Mylan acquires rights to novel LAMA respiratory compound from Pfizer Mylan announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist, or LAMA, compound for various indications.
http://www.theflyonthewall.com/permalinks/entry.php/ATHX;PFEid1936288/ATHX;PFE-Athersys-confirms-completion-of-patient-enrollment-of-Pfizers-MultiStem-study
http://www.theflyonthewall.com/permalinks/entry.php/ATHX;PFEid1936288/ATHX;PFE-Athersys-confirms-completion-of-patient-enrollment-of-Pfizers-MultiStem-study
No comments:
Post a Comment